Markets:

Overview

News

Currencies

International

Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.330 +0.040 (+3.10%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections

September 25, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

September 22, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Completes Surface Oncology Acquisition

September 08, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Why Coherus BioSciences Stock Popped Today ↗

August 03, 2023

The immuno-oncology leader delivered a strong second quarter.

Via The Motley Fool

Analyst Ratings for Coherus BioSciences ↗

August 03, 2023

Via Benzinga

Earnings Preview For Coherus BioSciences ↗

August 01, 2023

Via Benzinga

10 Analysts Have This to Say About Coherus BioSciences ↗

July 14, 2023

Via Benzinga

Why Coherus BioSciences Stock Was Plunging This Week ↗

September 08, 2023

The "index effect" is real, although typically not long-lasting.

Via The Motley Fool

Airbnb, Blackstone Rise On News They'll Join S&P 500 Index ↗

September 02, 2023

ABNB and BX will join Sept. 18 as part of a quarterly rebalancing.

Via Investor's Business Daily

Topics Stocks

Coherus BioSciences to Participate at Upcoming September Investor Conferences

September 01, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences

August 31, 2023

Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting

From Surface Oncology, Inc.

Via GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

August 22, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday ↗

August 03, 2023

U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Traeger, Inc. (NYSE: COOK) shares jumped 43.2% to $5.90...

Via Benzinga

Why Cummins Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

August 03, 2023

Gainers Bluejay Diagnostics, Inc. (NASDAQ: BJDX) shares jumped 75% to $9.60.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 02, 2023

Via Benzinga

Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights

August 02, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023

July 26, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗

July 24, 2023

Via Benzinga

Coherus BioSciences Announces New Employment Inducement Grants

July 21, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

July 20, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Mark Cuban's Pharmacy Company Lands Deal With Top 10 US Retailer: Here Are The Details ↗

July 19, 2023

Since launching the Mark Cuban Cost Plus Drug Company in 2022, entrepreneur and NBA team owner Mark Cuban has been on a mission to lower the cost of medicines for consumers.

Via Benzinga

Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™

July 13, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Cramer Is Still Bullish On AI Company Up 155% YTD: 'I Remain A Buyer' ↗

July 11, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he's surprised by the slow progress of Rambus Inc. (NASDAQ: RMBS).

Via Benzinga

Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.

July 03, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability ↗

June 20, 2023

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc.

Via Benzinga

Nasdaq Down 80 Points; US Consumer Sentiment Surges To 4-Month High In June ↗

June 16, 2023

U.S. stocks traded lower toward the end of trading, with Nasdaq Compsoite dropping around 80 points on Friday. The Dow traded down 0.24% to 34,324.18 while the NASDAQ fell 0.59% to 13,701.06. The S&P...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 16, 2023

Via Benzinga

Stocks Headed For Strong Weekly Wins ↗

June 16, 2023

Stocks are struggling for direction midday, but all three major indexes are on track for strong weekly gains.

Via Talk Markets

Why Squarespace Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 16, 2023

Gainers Oncorus, Inc. (NASDAQ: ONCR) shares surged 258% to $0.2781.

Via Benzinga

Crude Oil Rises; Adobe Posts Upbeat Results ↗

June 16, 2023

U.S. stocks traded slightly higher midway through trading, with Dow Jones gaining around 20 points on Friday. The Dow traded up 0.06% to 34,428.13 while the NASDAQ rose 0.05% to 13,789.23. The S&P 500,...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.